Benzinga's Bulls And Bears Of The Week: Apple, Amazon, Biogen, Bitcoin, Tesla And More

  • Benzinga has examined the prospects for many investor favorite stocks over the past week.
  • The past week's bullish calls included the e-commerce leader, a top biotech and the airlines.
  • The iPhone maker, the top cryptocurrency and a COVID-19 vaccine maker were among the bearish calls seen.

The big three U.S. indexes offered mixed signals last week, with the Nasdaq ending almost 2% higher, the S&P 500 up fractionally and the Dow Jones industrials lagging with almost a 1% retreat.

The S&P 500 did manage to eke out a new record high last week, but overall, Wall Street seemed to be in wait and see mode, with speculation that the reopening cycle may have already peaked, former drivers tech and financials still sputtering and ahead of the coming week's FOMC meeting. The Consumer Price Index came in hotter than expected, though the muted market reaction suggests inflation fears may have already been priced in.

Bucking the low volume trend last week were the meme stocks, which offered retail investors another wild ride. In addition, a notable FDA drug approval gave biotech stocks a bit of a boost. Still, some investment firms are anticipating a muted second half of the year for the markets.

The week also saw the Keystone Pipeline shut down, a major internet outage, the Worldwide Developers Conference and an agreement on a global corporate tax.

Through it all, Benzinga continued to examine the prospects for many of the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.

The Bulls

Although Amazon.com, Inc. AMZN has lagged other FAANG names over the last year, its growth momentum will continue. So says the investment strategist featured in Adam Eckert's "Stephanie Link Sees Continued Growth Momentum For Amazon Stock."

Be sure to check out Amazon Sidewalk: What Investors, Device Owners Should Know as well.

In "5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing," Shanthi Rexaline reveals why some see a strong drug launch ahead for Biogen Inc BIIB.

Also read 3 Major Trends in Biotech that are Revolutionizing Medical Research.

"MKM Partners Initiates Coverage On Airline Sector, Names Delta Top Pick" by Wayne Duggan examines expectations for Delta Air Lines, Inc. DAL and its peers as Americans take to the sky again.

Phil Hall's "UBS Analyst Upgrades Target: What You Need To Know" discusses why Target Corporation's TGT valuation is modest compared to its peers and there is more to come from the retailer this year.

For more on Target, see Target Hikes Quarterly Dividend by 32%.

In Priya Nigam's "JPMorgan Upgrades UPS After Recent Sell-Off," discover why the United Parcel Service, Inc. UPS investor day impressed one top analyst, who now sees an "attractive entry point" for the shares.

The Bears

"Apple Will Find It Hard To Recover From Fallout Over App Store Policies, Says Bill Gurley" by Madhukumar Warrier explores how Apple Inc. AAPL could have avoided the mess in which it finds itself.

On the other hand, check out Apple Options Traders Pile In Despite Market Uncertainty.

In Adrian Zmudzinski's "Bitcoin Might Be Entering A Bearish Market, JPMorgan Analysts Suggest," find out what signal one top analyst sees as pointing to a bear market for Bitcoin BTC/USD despite its recent price movements.

See Is The Game Over For Bitcoin? Why Crypto Influencers Think 'It Could Get Worse' for more low expectations for this top cryptocurrency.

Wayne Duggan's "2 Reasons Why Tesla Has Become An EV Stock Laggard" shows that there has been a clear shift in investor sentiment toward Tesla, Inc. TSLArelative to other electric vehicle stocks.

Tesla's Stock Steers Into Triangle And Looks To Choose Direction offers a look at the chart at the end of a week full of good news and bad for the EV leader.

The Moderna, Inc. MRNA stock run could be over as COVID-19 fades from the headlines, according to "Why BofA Is Bearish On Moderna Despite COVID-19 Vaccine Success" by Shanthi Rexaline.

In "BofA Downgrades Clover Health After 100% Stock Surge," Priya Nigam looks at how recent price moves have overshadowed the prospects for meme stock Clover Health Investments Corp CLOV.

Keep up with all the latest breaking news and trading ideas by following Benzinga on Twitter.

Posted In: AmazonAmazon.comAppleBiogenBitcoinClover Health InvestmentsDelta Air LinesModernaTargetTeslaUnited Parcel ServiceupsCryptocurrencyLong IdeasShort IdeasMarketsTrading Ideas

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.